8-K: CalciMedica Secures $32.5 Million Credit Facility to Extend Cash Runway into Mid-2026

CalciMedica has secured a credit facility for up to $32.5 million to support the development of its product pipeline and extend its cash runway.

Summary

• CalciMedica, Inc. has entered into a loan agreement with Avenue Venture Opportunities Fund II, L.P. for up to $32.5 million.
• The loan is structured in three tranches: $10 million was funded on February 28, 2025 (Tranche 1).
• Up to $7.5 million will be available between September 1, 2025, and March 31, 2026, contingent on clinical trial milestones (Tranche 2).
• Up to $15 million may be available between October 1, 2025, and March 31, 2026, subject to additional milestones and mutual agreement (Tranche 3).
• Interest-only payments are required until the 18-month anniversary of the closing date, with a possible 6-month extension.
• The loan's interest rate is the greater of (a) 5.00% plus the prime rate or (b) 12.75%.
• The loan matures on September 1, 2028.
• The lender has conversion rights for up to $2 million of the loan principal into common stock at 120% of the stock purchase price.
• A warrant to purchase 641,163 shares of common stock at $2.32 per share was issued to the lender.
• The company expects the initial tranche to fund operations into mid-2026.

Sentiment

Score: 7

Explanation: The sentiment is positive due to securing funding, extending the cash runway, and potential for clinical milestones. However, the debt and potential dilution temper the enthusiasm.

Positives

• The credit facility provides CalciMedica with additional financial flexibility.
• The initial $10 million tranche extends the cash runway into mid-2026.
• The loan agreement does not contain any minimum cash requirement or other financial covenants.
• Additional tranches are available upon achievement of clinical milestones, providing further funding opportunities.
• The company retains the option to prepay the loan, subject to a prepayment premium.

Negatives

• The loan is secured by a lien on all of the company's assets, including intellectual property.
• The lender has conversion rights, which could dilute existing shareholders.
• The company will pay a final payment equal to 3.75% of the aggregate principal amount of the Loan funded.
• The loan agreement includes customary events of default that could trigger immediate repayment.

Risks

• Failure to achieve clinical trial milestones could prevent access to additional tranches of funding.
• The variable interest rate exposes the company to potential increases in borrowing costs.
• The lender's conversion rights could dilute existing shareholders.
• Events of default could trigger immediate repayment of the loan.
• The company's assets, including intellectual property, are pledged as collateral.

Future Outlook

CalciMedica expects the initial tranche of the credit facility to fund operations into the middle of 2026 and anticipates multiple critical milestones throughout 2025.

Management Comments

• Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica, stated that the credit agreement provides additional flexibility as the company prepares for multiple critical milestones throughout 2025.
• She also noted that the facility extends the cash runway to the middle of 2026, providing ample runway beyond the KOURAGE readout.
• Chad Norman, Senior Portfolio Manager of Avenue Venture Opportunities Fund, expressed support for CalciMedica's mission and the potential of Auxora.

Industry Context

This announcement reflects a trend of biopharmaceutical companies securing debt financing to support clinical development programs, particularly for companies with promising late-stage assets.

Comparison to Industry Standards

• The interest rate of the loan (greater of prime plus 5.00% or 12.75%) is within the typical range for venture debt financings in the biopharmaceutical industry.
• The inclusion of warrants and conversion rights is also a common feature of such deals, providing the lender with potential upside from the company's success.
• Companies like Madrigal Pharmaceuticals and Viking Therapeutics have also recently secured debt financing to advance their clinical programs.
• The size of the credit facility ($32.5 million) is comparable to other venture debt deals for companies at a similar stage of development.

Stakeholder Impact

• Shareholders may experience dilution if the lender exercises its conversion rights.
• Employees benefit from the extended cash runway, providing job security.
• Patients may benefit from the continued development of CalciMedica's therapies.
• Creditors are impacted by the new debt and lien on the company's assets.
• Suppliers may benefit from the company's continued operations.

Next Steps

• CalciMedica will continue to develop its product pipeline, including the Phase 2 KOURAGE trial of Auxora.
• The company anticipates data from the KOURAGE trial in 2025.
• CalciMedica plans to discuss the design of a Phase 3 program in acute pancreatitis with the FDA.
• The company will continue to support the ongoing Phase 1/2 trial in pediatric patients with asparaginase-induced pancreatic toxicity.

Key Dates